menu search

Neurocentria announces dr. thomas südhof to join the scientific advisory board

The appointment further strengthens the company’s scientific resources, including in neuronal function and synaptic transmission, which are central ...

January 13, 2023, 2:00 pm

Seastar medical submits investigational device exemption (ide) application to fda to study a novel therapy to reduce hyperinflammation in adult acute kidney injury patients

Building upon demonstrated clinical success, the pivotal study will evaluate the Selective Cytopheretic Device in adults with AKI requiring CKRT DENVE...

January 9, 2023, 1:25 pm

Algernon pharmaceuticals announces phase 2b study of ifenprodil for chronic cough

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has announced that it is planning a 180-patient, 90-day, Phase 2b clinical study of NP-120 (Ifenp...

January 9, 2023, 8:39 am

Wave life sciences: huntington's hypotheses, gsk collaboration catalysts to move the needle

Wave Life Sciences caught a strong bid throughout the bulk of 2022, with the trend extending into the new year. Its ...

January 8, 2023, 1:40 am

Top four forex books for beginners

There is a massive amount of articles, movie tutorials, tutorials, guides and, of course, novels which help know the functioning … Top four forex bo...

January 7, 2023, 7:04 am

Celularity’s placental-derived allogeneic cell therapy provides clinically meaningful benefit and durable biological effect in patients with moderate to severe crohn’s disease in phase 1, phase 1b/2a

Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support...

January 6, 2023, 1:10 pm

Fate therapeutics announces termination of collaboration agreement with janssen, pipeline prioritization, next-generation programs, and key 2023 initiatives

Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization...

January 5, 2023, 10:00 pm

Ultragenyx to present at the 41st annual j.p. morgan healthcare conference

NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the developmen...

January 4, 2023, 6:00 am

Maxcyte signs strategic platform license with catamaran bio to support its car-nk cell therapy programs

MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for ...

January 3, 2023, 9:05 pm

Mirum pharmaceuticals to present at the 41st annual j.p. morgan healthcare conference on january 10, 2023

FOSTER CITY, Calif.--( BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisi...

January 3, 2023, 4:02 pm

Avalon globocare reveals deployment of breakthrough fusion gene map technology

Avalon GloboCare Corp (NASDAQ:ALBT) revealed that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing comp...

January 3, 2023, 9:52 am

Update – oncoc4 announces first patient dosed in preserve-004, a phase 2 clinical trial of onc-392 in combination with keytruda® (pembrolizumab) in patients with platinum-resistant ovarian cancer

The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous clinic...

December 30, 2022, 3:43 pm

Nexcella, inc announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car t-cell meeting

Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...

December 28, 2022, 1:05 pm

Opus genetics announces acquisition of the rights to two gene therapy product candidates for inherited retinal diseases

Opus to advance preclinical development programs for BEST1– and RHO-related retinal diseases Deal expands Opus’ addressable patient population for...

December 28, 2022, 1:00 pm

Astria therapeutics: tailwinds building with novel treatment paradigm

ATXS has broken out from a 37-week price reversal. Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of swelling in...

December 24, 2022, 12:38 am

Tesla stock's elonovela continues — musk says he won't sell shares

Tesla stock eased again Friday after shedding nearly 9% Thursday. Elon Musk said he won't sell more Tesla stock for two years....

December 23, 2022, 8:56 am

novel wastewater treatment technology that completely eliminates the most persistent and toxic micropollutants from water

Swiss cleantech firm Oxyle has raised CHF 2.8m ($3m) in a pre-seed funding round to bring its innovative wastewater treatment technology to market. Th...

December 22, 2022, 12:59 pm

Biocardia letter to shareholders

SUNNYVALE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) — BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeu...

December 22, 2022, 12:00 pm

Arkk: doubling and tripling down on a losing bet

Cathie Wood offers a novel measure of profitability in marketing memos. Noted traditional value investo...

December 22, 2022, 11:19 am

Angion receives nasdaq notice regarding minimum bid price requirements

UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) — Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery...

December 22, 2022, 2:50 am


Search within

Pages Search Results: